Anticancer Compounds

Case ID:
OSU-16-53
Web Published:
5/2/2018
Description:

Technology Description

 

Oregon State University seeks a licensee or collaborative research and development partner to further develop and commercialize a family of newly identified anti-cancer compounds. All inquiries are welcome. Preclinical studies have demonstrated that these compounds are effective in inhibiting viability of Ewing's sarcoma cell lines. Ewing's sarcoma is the second most common type of primary bone cancer in children and young adults between ages 10 and 20 with about 400 new diagnoses in the US per year. One compound, ML111, exhibits high potency against some non-small cell lung cancer cells (nearly 200,000 new cases per year in US) and hematopoietic cancer cell lines. With regard to the latter, ML111 has been shown to be effective in killing acute myeloid leukemia (AML; over 20,000 new cases per year in US) cells from a subset of AML patients. This finding suggests that AML patients can be stratified to identify those exhibiting sensitivity to ML111, which may also result in the identification of a biomarker that is predictive of ML111 efficacy in treating AML. ML111, and some of our more potent analogs, are currently undergoing in vivo toxicity in mice and efficacy testing in a mouse xenograft model using patient-derived cancer cells. There may be an opportunity to collaborate with a university spinout company.

 

Features & Benefits

 

  • ML111 is relatively non-toxic to non-transformed human cells (human umbilical vein endothelial cells, HUVEC) and most other cancer cells.
  • ML111 (and additional analogs) are currently undergoing in vivo toxicity in mice and efficacy testing in a mouse xenograft model using patient-derived cancer cells.
  • ML111 and analogs represent a potential new class of anticancer therapeutics.

 

Applications

 

  • Ewing’s Sarcoma
  • Non-small cell Lung Cancer
  • Hematopoietic Cancer
  • Monocytic Lymphoma

 

Background of Invention

 

Ewing sarcoma (EwS) is the second most common type of primary bone cancer in children and young adults between the ages of 10 and 20. Approximately 70% of children with EwS can be cured by high-dose, aggressive chemotherapy if the disease is diagnosed early. However, the survival rate of children diagnosed after EwS has metastasized drops to less than 30%, and a durable cure is particularly difficult to achieve when tumors are located in the pelvis, ribs, or spine. Current treatment protocols include non-specific, highly toxic chemotherapy agents. Due to the toxicity of these treatments, 95% of survivors will have a chronic health problem and 80% will have a severe or life-threatening disease by age 45. Despite knowledge of the molecular etiology of EwS for over 30 years, a precision medicine-based strategy for the treatment of EwS does not exist. More effective treatments for EwS are needed, as are better treatments for non-small cell lung cancer, acute myeloid leukemia, and monocytic lymphoma.

 

Status

 

Patent Pending

 

 

Patent Information:
Category(s):
Therapeutics
For Information, Contact:
Joe Christison
IP & Licensing Manager
Oregon State University
541-737-9016
joe.christison@oregonstate.edu
Inventors:
Mark Leid
Elahe Esfandiari
Keywords:
Cancer
Sarcoma
Tumor
© 2018. All Rights Reserved. Powered by Inteum